RT Journal Article
T1 Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry.
T2 Factores de riesgo de mortalidad en pacientes con infección por SARS-CoV-2 y fibrilación auricular: datos del registro SEMI-COVID-19.
A1 Azaña Gómez, Javier
A1 Pérez-Belmonte, Luis M
A1 Rubio-Rivas, Manuel
A1 Bascuñana, José
A1 Quirós-López, Raúl
A1 Taboada Martínez, María Luisa
A1 Montero Hernandez, Esther
A1 Roque-Rojas, Fernando
A1 Méndez-Bailón, Manuel
A1 Gómez-Huelgas, Ricardo
A1 en nombre del grupo SEMI-COVID-19, 
K1 Anticoagulación
K1 Anticoagulation
K1 Atrial fibrillation
K1 COVID-19
K1 Factor de riesgo
K1 Fibrilación auricular
K1 Hospitalización
K1 Hospitalization
K1 Mortalidad
K1 Mortality
K1 Risk factor
AB Atrial fibrillation and associated comorbidities pose a risk factor for mortality, morbidity and development of complications in patients admitted for COVID-19. To describe the clinical, epidemiological, radiological and analytical characteristics of patients with atrial fibrillation admitted for COVID-19 in Spain. Secondarily, we aim to identify those variables associated with mortality and poor prognosis of COVID-19 in patients with atrial fibrillation. Retrospective, observational, multicenter, nationwide, retrospective study of patients hospitalized for COVID-19 from March 1 to October 1, 2020. Data were obtained from the SEMI-COVID-19 Registry of the Spanish Society of Internal Medicine (SEMI) in which 150 Spanish hospitals participate. Between March 1 and October 1, 2020, data from a total of 16,461 patients were entered into the SEMI-COVID-19 registry. 1816 (11%) had a history of atrial fibrillation and the number of deaths among AF patients amounted to 738 (41%). Regarding clinical characteristics, deceased patients were admitted with a higher heart rate (88.38 vs. 84.95; P>0.01), with a higher percentage of respiratory failure (67.2 vs. 20.1%; P0.01), with a higher percentage of respiratory failure (67.2 vs. 20.1%; P Previous treatment with DOACs and DOACs treatment during admission seem to have a protective role in patients with atrial fibrillation, although this fact should be verified in prospective studies.
YR 2022
FD 2022-03-10
LK http://hdl.handle.net/10668/22371
UL http://hdl.handle.net/10668/22371
LA en
LA es
DS RISalud
RD Apr 8, 2025